Summit Therapeutics (MEX:SMMT) FCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics FCF Margin %?

Summit Therapeutics MEX:SMMT 30 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Summit Therapeutics ranks worse than 104166.56% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Summit Therapeutics's Free Cash Flow for the three months ended in Jun. 2026 was MXN-2,478.33 Mil. Summit Therapeutics's Revenue for the three months ended in Jun. 2026 was MXN0.00 Mil. Therefore, Summit Therapeutics's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Summit Therapeutics's current FCF Yield % is -3.34%.

The historical rank and industry rank for Summit Therapeutics's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of Summit Therapeutics was 523.13%. The lowest was -5986.67%. And the median was -2075.49%.

MEX:SMMT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -76.29
* Ranked among companies with meaningful FCF Margin % only.

Summit Therapeutics FCF Margin % Related Terms

Summit Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics FCF Margin % Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,029.44 -5,986.53 0.00 0.00 0.00

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:SMMT vs TECH, AXSM, KRYS: FCF Margin % Comparison

For the Biotechnology subindustry, Summit Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's FCF Margin % falls into.


MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Summit Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5826.411/0
= %

Summit Therapeutics's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-2478.334/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Summit Therapeutics (MEX:SMMT) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Summit Therapeutics and its competitors. According to the industry distribution chart, Summit Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Summit Therapeutics' FCF Margin % too high?
Summit Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Summit Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' FCF Margin % compare to TECH and AXSM?
According to the Biotechnology industry distribution chart, Summit Therapeutics ranks #999999 out of 960 companies for FCF Margin %. This places Summit Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Summit Therapeutics and its competitors. Summit Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price